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MLD, also called Arylsulfatase A deficiency is a lysosomal storage disease which 
is commonly listed in the family of leukodystrophies It is caused by the enzyme 
deficiency arylsulfatase A(ARSA) and  is characterized by enzyme activity in 
leukocytes that is less than 10% of normal controls. However, assay of the ARSA 
enzyme activity alone is not sufficient for diagnosis; ARSA Pseudodeficiency, 
which is characterized by enzyme activity that is 5-20% of normal controls does 
not cause MLD. A recent study indicates sulfatide is not completely responsible 
for MLD because it is nontoxic, instead  lysosulfatide, which has its acyl group 
removed, plays  cytotoxic  role  in vitro.
In addition  there is a ‘pseudo’-deficiency  that affects 7%-15% of the population. 
People with the pseudo deficiency do not have any MLD problems unless they have 
affected status. With the current diagnostic tests, Pseudo-deficiency reports as low 
enzyme levels but sulfatide is processed normally so MLD symptoms do not exist. 
The incidence of MLD that has autosomal recessive inheritance pattern. is estimated 
to occur in 1 in 40, 000 to 1 in 160, 000 individuals worldwide, but  much higher  in 
certain genetically isolated populations, in jewish. There are several forms of MLD, 
which are late infantile, juvenile, and adult. The late infantile form is the most 
common form  in which affected children display walking difficulty after the first 
year of life, Symptoms include muscle weakness, rigidity, developmental delays, 
progressive loss of vision leading to convulsions, impaired swallowing, paralysis, 
and dementia. Untreated, most die by age 5. Children with the juvenile form onset 
between 3 and 10 years of age usually with impaired school performance, and 
dementia, then develop symptoms similar to the late infantile form but with slower 
progression.The adult form that consists  of 15 to 25 percent of the cases can  appear 
at any age after puberty.  It presents as a psychiatric disorder or progressive dementia. 
Adult-onset MLD progresses more slowly than the late infantile and juvenile forms, 
Carriers have low enzyme levels “ but adequate to process the body’s sulfatide 
MLD  diagnosis is often missed or delayed because it is not the first cause that 
comes to mind when a patient presents with symptoms. In young children, MLD is 
often confused with CP or other causes of developmental delay. In older children, 
it is frequently confused with Batten disease, ADHD or adolescent/puberty-related 
behavioral changes. In adults, psychological conditions are often suspected. .MRI 
of the brain may be the first indicative test a patient undergoes. It shows patterns of 
dysmyelination. Urine and blood samples are required for a formal diagnosis MRI 
is not definitive for  diagnosis since abnormal  findings could be  seen in  other 
conditions. The blood arylsulfatase A enzyme levels are measured first, followed 
by urine sulfatide levels and clinical analysis. An increased amount of sulfatide in 
the urine suggests MLD. While  low level of ASA enzyme in the blood is not a 
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definitive test for MLD because the low levels of ASA 
are also found in ASA pseudodeficiency, a condition that 
results in individuals having only 5% to 15% of ASA 
enzyme function. However, this deficiency does not 
pose a health risk and individuals do not develop MLD.
An evoked potential test and a nerve conduction velocity 
test may  also be performed.. These  tests can reveal a 
delayed or impaired response in brain and peripheral 
Nerves consequently.
Finally, molecular analysis, also called DNA testing, can 
be done to confirm a diagnosis of MLD. In many cases, 
this kind of test can even determine which one of the 
more than 110 MLD-associated alleles is present. This 
can be useful if the patient has a family history of MLD.
Treatment
Currently there is no treatment or cure for advanced 
MLD.and treatment  is limited to  symptom 
management. Presymptomatic late infantile MLD 
patients, as well as those with juvenile or adult MLD 
that are either presymptomatic or displaying mild to 
moderate symptoms, have the option of bone marrow 
transplantation (including stem cell transplantation), 
which is under investigation to see if it may slow down 
progression of the disease or stop its progression in 
the central nervous system. However, results in the 
peripheral nervous system have been less dramatic.
Several future treatment options are currently being 
investigated. These include gene therapy, enzyme 
replacement therapy (ERT), substrate reduction therapy 
(SRT), and potentially enzyme enhancement therapy.
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